Addex Therapeutics Ltd · SIX:ADXN
Addex Therapeutics — Investor Presentation (January 2015)
53 slides from Addex Therapeutics's investor presentation, January 2015
Slide 1: Corporate Presentation
Corporate Presentation January 2015
Slide 2: Disclaimer
Disclaimer These materials do not constitute or form part, or all, of any offer or invitation to sell or issue, neither in the United States of America nor elsewhere, or any solicitation of any offer to purchase or subscribe for, any securities, nor shall part, or all, of these materials or their di
Slide 3: Overview and background
Overview and background • Addex was founded in 2002 in Geneva, Switzerland • ADXN is traded on the SIX Swiss Stock Exchange since 2007 • Focus: pioneering oral small molecule allosteric modulation-based drug discovery and development • Invested more than CHF300m in building allosteric modulator plat
Slide 4: Addex today
Addex today • Restructuring completed - IP portfolio and allosteric modulator technology platform secured - Current headcount – 7FTE - Significantly reduced cash burn provides sound basis for restart • Restart plan in process of being executed - Government / academic / patient group collaborations e
Slide 5: Value drivers and competitive advantage
Value drivers and competitive advantage Leading allosteric • Proprietary 85,000 knowledge-based HTS library z • Proprietary HTS high-fidelity pharmacology systems drug discovery platform • Deep allosteric know-how & expertise • Proven mechanism, that has led to marketed products Validated therapeuti
Slide 6: Clinical Stage Pipeline
Clinical Stage Pipeline CLINICAL Molecule / IND Phase I Phase II Phase III Mechanism Enabling Dipraglurant – ADX48621 Dipraglurant-IR (mGlu5 NAM) – Parkinson’s disease levodopa induced dyskinesia (PD-LID) Dipraglurant (mGlu5 NAM) – focal cervical dystonia Prof. Dirk Dressler, Hanover Medical School
Slide 7: Preclinical Stage Pipeline
Preclinical Stage Pipeline PRECLINICAL CLINICAL Molecule / Assay Clinical Lead IND Mechanism Development Hit-to-Lead Optimization Candidate Enabling Phase I Phase II Phase III & Screening Selection Dipraglurant (mGlu5 NAM) – treatment resistant depression Prof. Pilc ADX71441 (GABA-BR PAM) – autism,
Slide 8: Discovery programs
Discovery programs Target R&D stage Indication Additional Information mGlu3 PAM HTS performed Cancer Neuroprotection achieved through modulation of screening hits Neuroprotection in PD growth factors mGlu8 PAM HTS performed Exploratory target mGlu8 activation has been linked to screening hits anxiet
Slide 9: Dipraglurant mGlu5 NAM
Dipraglurant mGluS NAM therapeutics
Slide 10: Dipraglurant (ADX48621) overview
Dipraglurant (ADX48621) overview • Metabotropic glutamate receptor 5 (mGlu5) inhibitor (negative allosteric modulator-NAM) discovered at Addex • Highly selective, oral, brain penetrant, small molecule, active in several preclinical models of anxiety, depression, PD and PD-LID • Developed in PD-LID a
Slide 11: Dipraglurant in Parkinson's disease
Dipraglurant in Parkinson’s disease 11
Slide 12: Basal ganglia circuit and changes in Parkinson's disease
Basal ganglia circuit and changes in Parkinson’s disease Circuit in the basal ganglia affected by Circuit in healthy basal Parkinson’s disease: ganglia denervation of the substantia nigra and Sensorimotor circuit superimposed loss of dopaminergic input into the on a coronal brain slice striatum caus
Slide 13: Rationale for targeting mGlu5 inhibition in PD-LID
Rationale for targeting mGlu5 inhibition in Parkinson’s disease L-Dopa induced dyskinesia (PD-LID) – Denervation of dopaminergic striatal neurons within the SNc combined with the non-physiological, pulsatile, stimulation of dopamine receptors induce profound pathological changes which result in dysk
Slide 14: Treatment options for PD-LID and development pipeline
Treatment options for PD-LID and development pipeline • Management of the L-Dopa dose/ extended release formulation; L-Dopa sparing concept – Balance good motor symptoms controls against occurrence of LID – Sustained release formulation of L-Dopa might even prolong the dyskinesia episodes – Infusion
Slide 15: Rat Haloperidol-induced catalepsy model of PD
Rat Haloperidol-induced catalepsy model of PD • Haloperidol is an antagonist of the dopamine D2 receptor and the haloperidol-induced catalepsy rodent model is used as an animal model for PD • Dipraglurant was tested in this model with oral doses of 1, 3, 10 and 30 mg/kg • Dipraglurant resulted in ro
Slide 16: Dipraglurant reduces dystonia and chorea in macaque PD-LID model
Dipraglurant is the first compound reported to reduce dystonia as well as chorea in the macaque PD-LID model 15 15 median dystonia (0-2 hr) median chorea (0-2 hr) **p <0.01 10 * p<0.05 10 ** * 5 5 0 0 vehicle 3 10 30 vehicle 3 10 30 dipraglurant (mg/kg) dipraglurant (mg/kg) All received L-Dopa All r
Slide 17: NHP receptor occupancy PET study
NHP Receptor occupancy PET study: dipraglurant is brain penetrant and dose-dependently occupies the mGlu5 receptors Monkey 1 Monkey 2 Poli et al SFN 2014 * * Total dose administered as i.v. infusion 17 Effect in the MPTP PD-LID macaque model correlates with mGlu5 receptor occupancy - A robust effect
Slide 18: Dipraglurant-IR PK/PD profile is ideal for PD-LID
Dipraglurant-IR PK/PD profile is ideal for PD-LID PK and PD in non-human primates PK in humans Vehicle – 10 mg/kg – 10 mg/kg – L-Dopa carbidopa – dipraglurant dyskinesia score plasma conc dyskinesia score 100/25mg 100 mg – 1800 plasma conc plasma conc 4 1600 1600 3.5 1400 1400 plasma conc (ng/mL) pl
Slide 19: Summary of dipraglurant clinical development
Summary of dipraglurant clinical development • Initial Phase 1 program of dipraglurant successful − Three studies: single & multiple ascending doses, gender/food effects − 132 subjects studied to date, including 30 older subjects − Pharmacokinetics of dipraglurant immediate release formulation (IR)
Slide 20: EU and US Phase 2A dipraglurant trial for PD-LID
EU and US Phase 2A dipraglurant trial for PD-LID • Primary objective: safety & tolerability • Secondary objective: • Dipraglurant taken exploratory efficacy with levodopa • Objective evaluation in the clinic • Dipraglurant titration on day 1 and 14 & 28 • Randomized, – Trained observer scores double
Slide 21: Dipraglurant reduces LID severity
Dipraglurant reduces LID severity • Dipraglurant reduced peak dose mAIMS (90 min after dosing) dipra placebo 35% * 30% Midday dose: 25% ‒ Day 1 (50mg): 19.9% vs 4.1% (p=0.042) * % reduction 20% ‒ Day 14 (100mg): 32.3% vs 12.6% (p=0.034) 15% ‒ Day 28 (100mg): 31.4% vs 21.5% 10% 5% Placebo response li
Slide 22: Patient-reported measurable clinical effects
Patient-reported measurable clinical effects “On” time with no dyskinesia - change from week -1 50 mg dose level 100mg dose level - MPTP monkey data indicates a similar effect on prolongation of L-Dopa efficacy - dipraglurant active in the haloperidol induced catalepsy model 22
Slide 23: Summary of Dipraglurant in Parkinson's disease/PD-LID
Summary of Dipraglurant in Parkinson’s disease/ PD-LID • Anti-dyskinetic effect: − MPTP monkey model of PD-LID − PD-LID patients • Adjunctive treatment of PD motor fluctuations: − Haloperidol catalepsy model − Increased anti-parkinsonian effect in MPTP monkey model − Tendency to improve on-time in P
Slide 24: Recent literature on mGlu5 NAMs in dyskinesia
Recent literature on the role of mGlu5 NAMs in the treatment of dyskinesia 1: Finlay C, Duty S. Therapeutic potential of targeting glutamate receptors in Parkinson's disease. J Neural Transm. 2014 Feb 21. [Epub ahead of print] PubMed PMID: 24557498. 2: Rascol O, Fox S, Gasparini F, Kenney C, Di Paol
Slide 25: Dipraglurant in Dystonia
Dipraglurant in Dystonia therapeutics 25
Slide 26: Dystonia
Dystonia • Dystonia are a heterogeneous group of movement disorders characterized by involuntary muscle contractions that force the body into abnormal, sometimes painful, movements and positions (postures) • Dystonia can affect a single part of the body (focal), multiple areas (segmental) or the who
Slide 27: Dystonia and Rationale for targeting mGlu5 inhibition
Dystonia and Rationale for targeting mGlu5 inhibition • Dystonia are neuro-functional rather than neuro-degenerative disorders. • Common altered features include: – subtle alterations in neuronal connectivity/ function – altered synaptic communication within the basal ganglia • Aberrant or maladapti
Slide 28: Dystonia treatments and development pipeline
Dystonia treatments and development pipeline • Physical therapy and massage, including sensory biofeedback techniques • Deep brain stimulation for inherited/idiopathic dystonias reduces severity of symptoms by approx. 50%, but significantly varies between individuals with DYT1 patients benefiting mo
Slide 29: Preclinical and clinical efficacy of dipraglurant in dystonia
Preclinical and clinical efficacy of dipraglurant in dystonia • Phase 2A studies in PD-LID Patients • PD-LID MPTP monkey (drug induced dyskinesia with features of dystonia) • DYT-1 mouse model (genetic dystonia) • Tottering mouse model (paroxysmal dystonia) 29
Slide 30: Preclinical and clinical efficacy of dipraglurant in dystonia
Preclinical and clinical efficacy of dipraglurant in dystonia Bézard et al Mov. Disord. 2014 Dipraglurant normalises altered synaptic transmission observed in the striatum of DYT1 mice –it also partially restored a normal LTD in striatal MSNs after repeated treatment (data not shown) 30 Sciamanna et
Slide 31: Dipraglurant development plan - outline
Dipraglurant development plan - outline • In preparation & financed − Open label PET imaging receptor occupancy trial to support dose for Phase 2B − Clinical pharmacology study – IR/ER − Investigator led Phase 2 POC trial to explore therapeutic potential in dystonic patients (Prof. Dressler) • Futur
Slide 32: Dipraglurant summary and conclusions
Dipraglurant summary and conclusions • Strong rational to develop dipraglurant for treatment in PD-LID: - Robust Phase 2A POC results in which immediate release formulation of dipraglurant has shown an optimal PK and PD profile for PD-LID - Novartis departure from field leaves dipraglurant as first
Slide 33: ADX71441 – GABAB R positive allosteric modulator
ADX71441 – GABABR positive allosteric modulator 33
Slide 34: Oral GABAB receptor PAM (ADX71441)
Oral GABAB receptor PAM (ADX71441) • ADX71441 is a novel, first-in-class, oral, small molecule activator of gamma- aminobutyric acid subtype B (GABAB) receptor function through positive allosteric modulation (PAM) • Activation of GABAB receptor is preclinically, clinically & commercially validated i
Slide 35: ADX71441 in Charcot-Marie-Tooth type 1A neuropathy
ADX71441 in Charcot-Marie-Tooth type 1A neuropathy 35
Slide 36: Rationale for developing ADX71441 in CMT1A
Rationale for developing ADX71441 in CMT1A • Charcot Marie Tooth (CMT) disorder is one of the most common inherited neuropathy and a duplication of the peripheral myelin protein 22 gene causes the most frequent subtype CMT1A. • CMT1A affects approximately 1 in 5,000 people worldwide. • Patients deve
Slide 37: GABAB and CMT1A
GABAB and CMT1A GABAB has been shown to regulate the production of PMP-22 Over production of peripheral myelin protein- 22 (PMP-22), causes the structure and function of the myelin sheath to be abnormal. 37
Slide 38: CMT1A treatments and development pipeline
CMT1A treatments and development pipeline • Non-invasive therapies (e.g. Exercise, physiotherapy, orthotics). • Surgery to straighten toes, lengthen heel cords or lower arches. • Drugs used off-label for the treatment of CMT1A include: − Anticonvulsants (e.g. Clonazepam and Gabapentin) to treat the
Slide 39: GABAb R Activation Therapy with ADX71441 in CMT Rats
GABAb R Activation Therapy with ADX71441 in CMT Rats Key results: Treatment of CMT • CMT rats showed an overexpression of PMP22 mRNA, axonal loss and reduced grip strength reflecting typical CMT1A features rats with ADX71441 ameliorates axonal survival which should be the primary • In a comparative
Slide 40: ADX71441 in addiction: nicotine, alcohol
ADX71441 in addiction: - nicotine - alcohol 40
Slide 41: Rationale for developing ADX71441 in addiction
Rationale for developing ADX71441 in addiction • GABA is the major inhibitory neurotransmitter in the brain and is implicated in the modulation of central reward processes. • Administration of GABAB receptor agonists or positive modulators decreased self-administration of various drugs of abuse. • F
Slide 42: GABAB receptor mechanism of action in alcohol addiction
GABAB receptor mechanism of action in alcohol addiction Dopaminergic ventral tegmental area (VTA) neurons that project to the nucleus accumbens (NAc) are under tonic inhibition by GABAergic interneurons within the VTA. GABA release from these neurons is in turn under negative regulation by the mu-op
Slide 43: Alcohol addiction treatments and development pipeline
Alcohol addiction treatments and development pipeline • Rehabilitation centres and mutual aid groups (e.g. Alcoholics anonymous). • Drugs such as: − Acamprosate (NMDA antagonist) prevents glutamatergic stimulation as well as activating GABA. Efficacious in combination with naltrexone. − Dilsulfiram
Slide 44: GABAB receptor mechanism of action in nicotine addiction
GABAB receptor mechanism of action in nicotine addiction Dopaminergic neurons in the VTA receive two main excitatory inputs from both cholinergic and glutamatergic neurons both of which can be stimulated by nicotine. A number of nicotinic receptors are present on the dopaminergic neurons. These neur
Slide 45: Nicotine addiction treatments and development pipeline
Nicotine addiction treatments and development pipeline • Support groups and telephone counselling • Drugs such as: - Nicotine replacement therapy exists as gum, arm patch, lozenges, nasal spray (prescription) and inhaler (prescription) - Bupropion (antidepressant) used for smoking cessation. Multipl
Slide 46: ADX71441: preclinical validation in alcohol consumption model
ADX71441: preclinical validation in alcohol consumption model Cumulative intake of ethanol (g) ** ** * ** ** ** ** ** ** * ** * ** ** * * *p<0.05 **p<0.01 vs veh *p<0.05 **p<0.01 vs veh • ADX71441 resulted in robust and dose-dependent reductions of alcohol consumption in male mice with MED of 10 mg/
Slide 47: ADX71441 summary and conclusion
ADX71441 summary and conclusion • Strong rational to develop a GABA B PAM that has a differentiated profile to baclofen: - GABA B PAM is clinically validated by data generated with baclofen, an orthosteric agonist of the GABAB receptor - ADX71441 has a differentiated preclinical profile to baclofen:
Slide 48: Janssen partnership
Janssen partnership ADX71149: mGlu2 PAM • significant potential in treating CNS disorders 48
Slide 49: Overview of Janssen partnership (ADX71149)
Overview of Janssen partnership (ADX71149) • ADX71149 is a highly selective oral brain penetrant small molecule metabotropic glutamate receptor 2 (mGlu2) positive allosteric modulator (PAM) discovered in collaboration with Janssen Pharmaceuticals Inc.(JPI) • mGlu2 PAM is validated in multiple indica
Slide 50: Board, Management and Advisors
Board, Management and Advisors • Board: - Vincent Lawton, ex- MD of MSD, Member of MHRA Board • Management: - Tim Dyer, CEO/CFO - Sonia Poli, CSO & Head of Development - Robert Lutjens, Head of Discovery • Advisors: - PD-LID - Michael J. Fox Foundation for Parkinson’s Research - Prof. Tison, Dr. Béz
Slide 51: Financials and stock
Financials and stock • Cash runway into 2016 − CHF1.8M million in cash as of 31 December 2014 • Traded on SIX Swiss Exchange: ADXN (ISIN:CH0029850754) • 10,173,576 shares outstanding (11 million fully diluted) − Biotechnology Value Fund holds 13% • Analysts coverage: − Ladenburg Thalmann (New York)
Slide 52: Summary
Summary • Key strategic objectives − Secure resources to advance clinical pipeline − Collaborate with Industry / governments / academia / patient groups to advance clinical / preclinical / discovery programs • Sufficient financial resources & team to execute key strategy objectives • Support and val
Slide 53: allosteric modulators for human health
allosteric modulators for human health www.addextherapeutics.com
Addex Therapeutics — Investor Presentation (January 2015) on 6ix